首页 | 本学科首页   官方微博 | 高级检索  
     

基于UPLC-QTOF/MS的胆囊癌血清非靶向代谢组学研究
引用本文:袁道祎,韩 骏,韩敏露,刘武纬,谢 瑛. 基于UPLC-QTOF/MS的胆囊癌血清非靶向代谢组学研究[J]. 现代生物医学进展, 2020, 0(17): 3201-3206
作者姓名:袁道祎  韩 骏  韩敏露  刘武纬  谢 瑛
作者单位:上海交通大学医学院药理学与化学生物学系 上海 200021;1 上海交通大学医学院药理学与化学生物学系 上海 200021;2 中国人民解放军海军军医大学东方肝胆医院肝胆外科 上海 200433
基金项目:国家重点研发计划项目(2017YFC1309701);国家十三五科技重大专项(2017ZX09304016);十三五新药创制重大专项(2018ZX09734005)
摘    要:目的:胆囊癌(Gallbladder carcinoma,GBC)是一种常见的胆道系统恶性肿瘤,五年生存率极低,目前临床上缺少有效的诊断标志物。故本研究探索胆囊癌患者与健康人血清的差异性小分子代谢物,用于胆囊癌的定性诊断。方法:本研究以超高效液相色谱联用四极杆飞行时间质谱(UPLC-QTOF/MS)技术为平台,以32例胆囊癌患者和32例健康人血清为研究对象,进行非靶向代谢组学研究分析,用SIMCA-P软件进行PCA和OPLS-DA建模分析,结合T检验结果和代谢物在两组中的差异倍数来筛选潜在小分子代谢标志物,并通过二元逻辑回归分析建立联合诊断模型。结果:溶血磷脂酰胆碱(18:1)(LysoPC(18:1))和十八烷胺(Octadecylamine,ODA)两个代谢物在胆囊癌患者和健康对照组血清中具有显著性差异,差异倍数达到2倍以上。经过二元逻辑回归分析建立诊断模型,两者构建联合诊断的诊断模型为Logit[P=GBC]=26.090*[LysoPC(18:1)]-8.877*[ODA]-113.075,据此建立受试者工作特征曲线(Receiver operating characteristic,ROC)曲线,曲线下面积(Area under the curve,AUC)为0.986,灵敏度为97.1%,特异性为94.6%。结论:LysoPC(18:1)和ODA可作为胆囊癌的潜在诊断标志物,为胆囊癌的诊断提供参考。

关 键 词:胆囊癌;代谢组学;标志物
收稿时间:2020-02-27
修稿时间:2020-03-23

UPLC-QTOF/MS Based Serum Untargeted Metabolomics Study of Gallbladder Carcinoma
YUAN Dao-yi,HAN Jun,HAN Min-lu,LIU Wu-wei,XIE Ying. UPLC-QTOF/MS Based Serum Untargeted Metabolomics Study of Gallbladder Carcinoma[J]. Progress in Modern Biomedicine, 2020, 0(17): 3201-3206
Authors:YUAN Dao-yi  HAN Jun  HAN Min-lu  LIU Wu-wei  XIE Ying
Affiliation:Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200021, China;1 Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200021, China; 2 Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200433, China
Abstract:ABSTRACT Objective: Gallbladder carcinoma (GBC) is a common malignancy of the biliary tract system, with a poor five-year survival rate and for lack of effective diagnostic biomarkers. Thus the aim of this study is to explore the different small metabolites in serum of GBC patients and healthy subjects. Methods: Based on the Ultra-performance liquid chromatography tandem quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) technique, serum untargeted metabolomics studies of 32 GBC patients and 32 healthy controls were developed. Potential biomarkers were screened by PCA and OPLS-DA analysis using SIMCA-P software, followed by t-test and fold change analysis. Then a diagnostic model was established. Results: The levels of LysoPC(18:1) and Octadecylamine (ODA) in GBC patients serum had changed (>2-fold change). A diagnostic panel based on these two metabolites for the detection of GBC was constructed as follows: Logit[P=GBC]=26.090*[LysoPC(18:1)]-8.877*[ODA]-113.075. The receiver operating characteristic (ROC) curve analysis of a combination of LysoPC(18:1) and ODA was then conducted. Outstanding discrimination has been achieved with area under the curve (AUC) of 0.986, sensitivity of 97.1% and specificity of 94.6%. Conclusion: LysoPC(18:1) and ODA can be used for discrimination between GBC patients and healthy subjects.
Keywords:Gallbladder Carcinoma   Metabolomics   Biomarker
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号